HealthBeacon launches its integrated Smart Scale
Dublin, 15 July 2022: Healthbeacon plc, the leading digital therapeutics company that develops products for managing injectable medications for patients in the home, has today announced the launch of its new Smart Scale, an integrated solution that forms part of its Injection Care Management System (ICMS).
The HealthBeacon Smart Scale enables patients to add weight monitoring to its ICMS, as the connected weight scale tracks weight progression, providing clinical teams with insights on specific medication outcomes.
There are currently nine million patients in the U.S. that self-administer injectable medications in the home, and many require their weight to be carefully managed and monitored. HealthBeacon's integrated Smart Scale will sync seamlessly with its ICMS, helping patients improve adherence to therapies and providing healthcare practitioners with access to important clinical data.
HealthBeacon provides each member of its injection care management system with a Smart Sharps Bin, a companion app, a more sustainable waste management service, and now, the integrated Smart Scale. This enhances a system that already improves the likelihood of success on therapy by increasing adherence by as much as 26% and persistence by 19% according to peer reviewed research.
It is expected that the HealthBeacon Smart Scale will become available to HealthBeacon patients this autumn.
Commenting, HealthBeacon CEO and co-founder, Jim Joyce, said: "The launch of the HB Smart Scale is an important step as we strive to improve injection adherence globally. Weight management is an important factor in the health of many patients that are required to self-administer injectable medications at home. This product integrates seamlessly into our technology which patients are already using, meaning this addition can improve their health with no added level of complexity."
The announcement of the launch of HealthBeacon's Smart Scale was made at the annual MAGIC conference in Chicago, the largest patient conference for children with growth disorders. The monitoring of weight progression is of particular importance to children suffering from growth disorders.
Commenting further, Mr Joyce said: "We know how difficult it is for families that must administer injections to their children at home. For children on growth hormones, it can be difficult to both manage injections and monitor growth progress. HealthBeacon's Smart Scale will support affected families by enabling parents to track their child's growth along with monitoring injection adherence. It also benefits children as they become teenagers and can administer medication themselves, providing them with a level of independence while enabling their parents to continue to monitor their adherence and track their growth."
|
Enquiries: |
|
| HealthBeacon: Laurence Flavin
|
|
| Goodbody (Euronext Listing Sponsor and Broker): David Kearney |
+353 (1) 667 0420 |
| Stephen Kane |
|
|
Drury (Public Relations): |
|
| Billy Murphy |
+353 (0) 87 231 3085 |
| Cathal Barry |
+353 (0) 87 227 9281 |
Ends
About HealthBeacon
Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company that develops products for managing injectable medications for patients in the home. The HealthBeacon Injection Care Management System tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools, and artificial intelligence (AI) driven data analytics. The Company operates across Europe, North America and the United Kingdom and employs more than 70 people and has obtained more than 30 design and utility patents. Peer reviewed evidence supports a 19% improvement in therapy persistence by patients and up to 26% improvement in adherence to therapy, which improves clinical outcomes and significantly improves efficiency in health systems. The Company's mission is to become the world's leading digital therapeutics platform for injectable medications.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.